Several new cancer drugs have made progress, keystone pharmaceutical stocks bucked the trend, up more than 9%

On August 26, 16.0867 million restricted shares were released today, bucking the trend of the lifting of the ban on cornerstone pharmaceutical sepsis B (2616.HK), which is now trading at HK$10.98, up 9.15 per cent, with a provisional turnover of HK$6.48 million, with a new market capitalisation of HK$11.1 billion.
analysis may be related to the recent critical development of several of the company's new drug development. From August 22 to August 25, Keystone Pharmaceuticals issued three announcements, introducing new developments in the field of cancer treatment.
Cornerstone Pharmaceuticals announced on the 22nd that the anti-tumor inhibitor CS3002 has completed the Phase I trial in Australia, the relevant research will be carried out soon.
CS3002 is a selective inhibitor of cell cycle protein-dependent kinase 4 and 6 ("CDK4/6") developed by Keystone Pharmaceuticals. By specifically inhibiting CDK4/6 in order to induce the cell cycle stagnation of tumor cells, CS3002 has shown broad application prospects for a wide range of solid tumors in combination endocrine therapy or immunocheckpoint inhibitor therapy. Currently, three CDK4/6 inhibitors have been approved by the FDA. A CDK4/6 inhibitor has also been approved in China to treat breast cancer.
the same day, Keystone Pharmaceuticals also announced that the 2019 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2019 Annual Meeting) has accepted three clinical studies abstracts from Keystone Pharmaceuticals, three key cancer immunotherapy candidates CS1001 (anti-PD-L1 monotophosis), CS1002 (anti-CTLA-4 monotophos) and CS1003 (anti-PD-1 monotophoid). At the same time, three other recent breakthrough studies in the CS1001-101 Ib clinical study have been submitted for presentation.On August 25,
, Keystone Pharmaceuticals announced that avapritinib's I/II phase bridge registration trial, developed by Cornerstone Pharmaceuticals Partner Blueprint Medicines Corporation, would enable the first subject-administered drug in China. Avapritinib is an oral, potent, highly selective KIT and PDGFRA inhibitor. Published preclinical data indicate that avapritinib has a strong inhibitory effect on GIST-related GET-related GETandal and GiST-related DGFRA mutant kinases.
.